Less Ads, More Data, More Tools Register for FREE

Pin to quick picksORPH.L Regulatory News (ORPH)

  • There is currently no data for ORPH

Senior Management Appointments

9 Apr 2013 07:00

RNS Number : 8582B
Venn Life Sciences Holdings PLC
09 April 2013
 



 

Venn Life Sciences Holdings Plc

("Venn" or the "Company")

 

Senior Management Appointments

 

Venn Life Sciences (AIM: VENN), a growing Clinical Research Organisation (CRO) providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, announces the appointment of Nigel Trim and Jamie Chorlton as Managing Director and VP Operations respectively, with immediate effect. These are not Board appointments.

 

Nigel has worked extensively across Europe, CEE and South East Asia in the healthcare industry, spanning over 30 years. A graduate pharmacologist, Nigel brings a wealth of clinical trial expertise to Venn, coupling clinical operations with senior management roles such as sales and marketing. Experienced in M&A, creating and managing growth, he has successfully built and sold several companies and was most recently the European Managing Director of an international CRO.

Jamie brings to Venn 16 years of clinical research experience, gained in CRO, large pharmaceutical and biotech environments. After obtaining a degree in Biomedical Technology, Jamie acquired significant therapeutic expertise, working in both pharmaceutical and medical device clinical trial settings. For the last seven years, Jamie has directed European clinical operations for a global mid-tier CRO and has played a key role in the successful growth of that organisation.

 

Commenting on the appointments, Venn CEO, Tony Richardson, said: "We see both these appointments as the next step in terms of Venn increasing its profile and operations internationally. We are building a dynamic organisation throughout Europe and we will achieve that through attracting the right people."

 

Enquiries:

 

Venn Life Sciences Holdings Plc

Tony Richardson, Chief Executive Officer

Tel: +353 154 99 341

Orla McGuinness, Marketing Manager

Tel: +33 676 93 11 78

Zeus Capital (Nominated Adviser and Broker)

Ross Andrews/Andrew Jones(Corporate Finance)

Tel: 0161 831 1512

John Goold (Institutional Sales)

Tel: 020 7016 8925

Walbrook PR Ltd

Tel: 020 7933 8787 or venn@walbrookpr.com

Paul McManus

Mob: 07980 541 893

Lianne Cawthorne

Mob: 07584 391 303

 

Additional Information:

 

About Venn Life Sciences Limited: www.vennlifesciences.com

Venn Life Sciences is a Clinical Research Organisation ("CRO") providing a suite of clinical trial management services to pharmaceutical, biotechnology and medical device organisations. With operations in France, Ireland, the Netherlands, Russia, the UK, and a branch office in Switzerland, the Venn Group also includes a Clinical Resourcing business placing experienced clinical teams and individuals on projects throughout Europe. The Company's near term objective is the expansion of its coverage to other European countries through strategic acquisitions and organic growth, offering clients a full service, multi-centred capability in Phase II-IV trials and across a range of principal disease areas.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCUGUGACUPWGQR
Date   Source Headline
11th Jun 20207:00 amRNSMajor New Contract Signed
10th Jun 20205:40 pmRNSHolding(s) in Company
10th Jun 20205:35 pmRNSHolding(s) in Company
10th Jun 20205:30 pmRNSHolding(s) in Company
4th Jun 20207:00 amRNSLaunch of Covid-19 Antibody Testing
29th May 20208:00 amRNSEuronext Growth Dublin Notice
22nd May 202010:53 amRNSResults of Fundraising
22nd May 20207:01 amRNSPrimaryBid.com Offer
22nd May 20207:00 amRNSProposed Fundraising to raise up to £12 million
18th May 20209:05 amRNSSecond Price Monitoring Extn
18th May 20209:00 amRNSPrice Monitoring Extension
18th May 20207:00 amRNSUpdate on antibody test and share price movement
11th May 20207:00 amRNSAppointment of Joint Broker
11th May 20207:00 amRNSNew COVID-19 Antibody Testing Partnership
4th May 20207:00 amRNSMajor New Contract and Directorate Change
23rd Apr 20207:00 amRNSTesting of anti-viral for treating COVID-19
14th Apr 20202:06 pmRNSSecond Price Monitoring Extn
14th Apr 20202:01 pmRNSPrice Monitoring Extension
23rd Mar 20204:43 pmRNSSecond Price Monitoring Extn
23rd Mar 20204:37 pmRNSPrice Monitoring Extension
20th Mar 20202:06 pmRNSSecond Price Monitoring Extn
20th Mar 20202:00 pmRNSPrice Monitoring Extension
16th Mar 20207:00 amRNSPublication of positive results in journal
12th Mar 20203:32 pmRNSHolding(s) in Company
12th Mar 20209:00 amRNSHolding(s) in Company
12th Mar 20208:00 amRNSEuronext Growth Dublin Notice
10th Mar 20207:00 amRNSPublication of Positive Results in Journal
9th Mar 20204:53 pmRNSCompletion of Compulsory Acquisition of Shares
9th Mar 20207:00 amRNSCoronavirus Challenge Study Model
6th Mar 20207:00 amRNSNew Contract
3rd Mar 20208:00 amRNSEuronext Growth Dublin Notice
2nd Mar 20203:25 pmRNSChange in Registered Office
27th Feb 20207:00 amRNSAppointment of new Director
26th Feb 20203:04 pmRNSResult of Rule 15 Offer and Total Voting Rights
21st Feb 20207:00 amRNSInvestor Event Attendance and Presentation
20th Feb 20207:00 amRNSAppointment of Chair of Advisory Board
20th Feb 20207:00 amRNSAppointment of Chair of Advisory Board
13th Feb 20207:00 amRNSAppointment of Group Chief Financial Officer
11th Feb 20208:00 amRNSEuronext Growth Dublin Notice
10th Feb 202011:17 amRNSValue the Markets Webinar
7th Feb 20206:08 pmRNSHolding(s) in Company
7th Feb 20203:42 pmRNSSignificant shareholder
7th Feb 20207:00 amRNSInvestor Event Attendance and Presentation
6th Feb 20209:30 amRNSTotal Voting Rights
6th Feb 20208:00 amRNSEuronext Growth Dublin Notice
6th Feb 20207:00 amRNSUpcoming Investor Events
5th Feb 202011:00 amRNSExercise of Warrants and Issue of Shares
3rd Feb 202010:30 amRNSNew Corporate Presentation
31st Jan 202011:23 amRNSResults of Placing and Subscription
31st Jan 20207:00 amRNSProposed Placing to raise a minimum of £5 million

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.